Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02543944 · ClinicalTrials.gov registry record · Phase 2
Improving Treatment Outcomes for Prescription Opioid Dependence
A Phase 2 study, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 2
- Development phase
- 117
- Enrollment target
NCT02543944 is a Phase 2 study that has completed, run by University of Arkansas. The registered enrollment target is 117 participants.
The verdict
NCT02543944, a Phase 2 study, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 117 participants
- Enrollment target
Study Summary
Overall, this proposal seeks to improve treatment strategies for the significant public health problem of prescription opioid dependence by determining whether gabapentin, a non-narcotic pharmaceutical agent with minimal abuse potential and preliminary efficacy, will be effective in ameliorating withdrawal symptoms, craving and illicit drug use in prescription opioid dependent participants undergoing a 10-day detoxification from buprenorphine. In addition, the acceptability and feasibility of transitioning to depot naltrexone therapy will also be determined. If successful, this study would provide data to support further development of gabapentin as a pharmacological tool for improved outcomes during opioid detoxification as well as an integrated outpatient approach for treating prescription opioid dependence.
Interventions
- DRUG Gabapentin
- DRUG Buprenorphine
- DRUG Clonidine
- DRUG Naltrexone (depot)
- DRUG Naltrexone (oral)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2016-02 |
| Est. Completion | 2021-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02543944
The ClinicalTrials.gov registry entry for NCT02543944 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Gabapentin is the first listed.
NCT02543944 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02543944 about?
NCT02543944 is a clinical study titled "Improving Treatment Outcomes for Prescription Opioid Dependence". Overall, this proposal seeks to improve treatment strategies for the significant public health problem of prescription opioid dependence by determining whether gabapentin, a non-narcotic pharmaceutical agent with minimal abuse potential and preliminary efficacy, will be effective in ameliorating wit...
What is the current status of trial NCT02543944?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 117 participants. The study started on 2016-02. Estimated completion is 2021-05-31.
What interventions are being tested in trial NCT02543944?
The interventions under investigation include: Gabapentin (DRUG), Buprenorphine (DRUG), Clonidine (DRUG), Naltrexone (depot) (DRUG), Naltrexone (oral) (DRUG).
Who is sponsoring clinical trial NCT02543944?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.